Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.

A West Australian-led study could solve the shortage of a life-saving drug with the results revealing a new treatment was ...

An international trial found combining a chemotherapy drug with an immunotherapy bladder cancer treatment is simple, safe and effective.The trial was ...

“Why is BCG the only thing that we're thinking about in these patients?” I think it's sparked a whole new era in how we're thinking about what the best first-line treatment for patients might be.

Urological cancers are malignancies that affect the organs of the urinary system and male reproductive system. Of these, bladder ...

BCG shortages are prompting ... including patient selection criteria, treatment pathways, and AE management. The importance of interdisciplinary collaboration was reiterated, with suggestions that ...

The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS ...

The treatment is administered sequentially ... Anktiva is co-administered with BCG, which simplifies logistics given that urology clinics already have extensive experience with BCG administration. In ...

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.